ArticleJournal of nanobiotechnology2025
Porphyromonas gingivalis extracellular vesicles promotes tumor metastasis in esophageal squamous cell carcinoma by inducing PRKACB/JNK/ NFATC2 axis.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Porphyromonas gingivalis (Pg), a common oral microorganism linked to periodontal disease, has been recently shown to play a significant role in oral and systemic health through the secretion of extracellular vesicles (EVs). Nevertheless, the implications of Porphyromonas gingivalis-derived extracellular vesicles (Pg-EVs) on esophageal squamous cell carcinoma (ESCC) metastasis and the corresponding underlying mechanisms continue to be shrouded in ambiguity. Our study aimed to determine whether and how Pg-EVs mediate ESCC metastasis. Using 16sRNA gene sequencing, FISH and bioinformatics we found that Pg was abundant in human ESCC cancerous tissues and was associated with poor prognosis in ESCC patients. Our results further revealed that Pg-EVs enhanced the migration and invasion of cancer cells, promoted extravasation and metastasis by inducing NFATC2 expression both in vitro and in vivo. Mechanistically, we identified that Pg-EVs induced a new pattern recognition receptor PRKACB to activate the JNK pathway, resulting in the upregulation of NFATC2.Interestingly, the abundance of Pg in tumor tissues of EC patients was positively associated with the expression levels of PRKACB and NFATC2. Moreover, high expression of PRKACB or NFATC2 was significantly associated with a shorter overall survival time of EC patients. Our findings suggest that Pg is highly prevalent in ESCC, and it is associated with poor prognosis, stage, and lymph node metastasis. As a consequence of increasing PRKACB expression, Pg-EVs activate the JNK pathway, resulting in an increase in NFATC2 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.